Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market

Cosmos Health begins UK sales of C-ScrubVet, adding an animal health line to support its long-term growth and profitability targets.

Rhea-AI Summary

Cosmos Health (COSM) has launched its new veterinary antimicrobial cleanser C-ScrubVet Wash 4% CHDG in the United Kingdom, marking its commercial entry into the approximately $69 billion global animal health market.

The product contains 4% chlorhexidine digluconate and is certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use. It is formulated for dogs, cats, horses, companion and large animals and supplied as a 500ml biocide for external use in a pump-dispenser bottle. Initial sales are e-commerce led in the UK, with additional European markets targeted from Q4 2026 and planned expansion into pet store chains and veterinary clinics.

C-ScrubVet is manufactured in-house at Cana Laboratories’ EU GMP-licensed, EMA-certified facility and extends the established C-Scrub brand beyond human healthcare. The company highlights this launch as a new growth channel alongside its core pharmaceutical and nutraceutical business, which generated record fiscal 2025 revenue of $65.27 million, up 20% year-over-year, and as one of several catalysts expected to support previously issued 2029 guidance of $200.6 million in revenue, $44.2 million in adjusted EBITDA and $31.0 million in net income.

Positive

• Record FY 2025 revenue of $65.27 million, up 20% year-over-year
• Previously issued 2029 guidance targets $200.6 million revenue, $44.2 million adjusted EBITDA and $31.0 million net income
• Entry into an estimated $69 billion global animal health market with projected 11% CAGR to 2033
• Veterinary product certified under EN 1656 and EN 1657, supporting bactericidal and fungicidal claims
• In-house EU GMP-licensed, EMA-certified manufacturing at Cana Laboratories supports margin control and quality
• Phased rollout beginning in UK with additional European markets from Q4 2026 and planned retail and clinic channels

Negative

• None.

News Explained

Cosmos Health says it has received first orders and commenced UK sales of C-ScrubVet, moving the animal-health entry into active commercial distribution; the release discloses no financing, ownership, or dilution terms.

Market Context

On Sep 3, COSM rose 18.72% after an update citing UK C-Scrub retail wins; the Sep 9 C-ScrubVet launc...

Analysis

On Sep 3, COSM rose 18.72% after an update citing UK C-Scrub retail wins; the Sep 9 C-ScrubVet launch extended that franchise into veterinary use, with first orders disclosed but no order value provided.

Key Figures

Market opportunity: $69 billion CHDG concentration: 4% Bottle size: 500ml +4 more

Market opportunity

$69 billion

Global animal health market

CHDG concentration

4%

C-ScrubVet Wash veterinary cleanser

Bottle size

500ml

Pump-dispenser bottle

European market expansion

Q4 2026

Additional European markets targeted

2029 revenue guidance

$200.6 million

Previously issued guidance

2029 adjusted EBITDA guidance

$44.2 million

Previously issued guidance

2029 net income guidance

$31.0 million

Previously issued guidance

Historical Context

1 past event · Latest: Sep 03

1 event

1. Sep 03

   C-Scrub retail expansion

   24h Move

   +18.7%

   UK C-Scrub retail wins and reaffirmed 2029 targets

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

chlorhexidine digluconate, biocide, eu gmp, bactericidal, +1 more

5 terms

chlorhexidine digluconate medical

"containing 4% chlorhexidine digluconate, effective against bacteria"

Chlorhexidine digluconate is a widely used antiseptic liquid that kills or reduces bacteria and other germs on skin, in the mouth, and on medical surfaces; think of it as a targeted disinfectant used in wound care, surgical prep, mouthwashes, and medical device cleaning. Investors care because its approval, supply, concentration rules, or safety concerns can drive demand, trigger regulatory action or recalls, and affect manufacturers’ sales and costs—similar to how changes in household-cleaner regulations can reshape a cleaning-products business.

biocide regulatory

"supplied as a biocide for external use"

A biocide is a chemical or biological agent designed to kill, deter, or control harmful organisms such as bacteria, fungi, insects or other pests; examples include disinfectants, preservatives and insecticides. It matters to investors because biocides are regulated products—approval, labeling and safety rules affect a maker’s ability to sell, the cost of compliance and potential liability; think of them like regulated consumer medicines for controlling unwanted organisms.

eu gmp regulatory

"Cana Laboratories, the Company's EU GMP-licensed"

EU Good Manufacturing Practice (EU GMP) is the European standard for how medicines, vaccines and related medical products must be produced and controlled to ensure consistent quality, safety and traceability. Think of it as a detailed recipe and inspection checklist that factories must follow; for investors, EU GMP compliance is a practical signal that a company can supply products reliably, avoid costly recalls or regulatory blocks, and access European markets.

bactericidal medical

"for bactericidal and fungicidal activity in veterinary use"

An agent or product that is bactericidal kills bacteria outright rather than merely stopping their growth; it reduces the number of live bacterial cells. This distinction matters to investors because bactericidal drugs, disinfectants, or medical devices can have different regulatory paths, market uses, and competitive value compared with agents that only inhibit bacteria, much like a fire extinguisher that puts out flames versus a barrier that only slows their spread.

fungicidal medical

"for bactericidal and fungicidal activity in veterinary use"

An agent or product described as fungicidal kills fungi rather than merely stopping their growth; it may work by disrupting fungal cell walls, membranes, or vital processes. Investors care because fungicidal labeling affects regulatory approvals, product claims, market positioning and liability exposure the way a pesticide that actually eliminates pests differs from one that only slows them, influencing sales, compliance costs and competitive advantage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet

• Formulated for dogs, cats, horses, companion and large animals, and supplied in a 500ml pump-dispenser bottle

• Sales have commenced in the United Kingdom, with additional European markets to follow from Q4 2026

• Multichannel strategy initially focused on e-commerce, with planned expansion into pet store chains and veterinary clinics

• Certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use

• Manufactured in-house at Cana Laboratories' EU GMP-licensed, EMA-certified facility, consistent with the Company's vertically integrated model

• Extends the C-Scrub franchise beyond human healthcare, addressing the $69 billion global animal health market

• Expected to be one of several catalysts supporting the Company's previously issued 2029 guidance of $200.6 million in revenue, $44.2 million in adjusted EBITDA and $31 million in net income

CHICAGO, IL / ACCESS Newswire / September 9, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet.

C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial cleanser containing 4% chlorhexidine digluconate, effective against bacteria, fungi and enveloped viruses. It is formulated for dogs, cats, horses, companion and large animals, and is supplied as a biocide for external use in a 500ml pump-dispenser bottle. The product is certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity in veterinary use.

The Company expects the line to benefit from a number of operational advantages:

• Established formulation - C-ScrubVet builds on the Company's existing C-Scrub Wash 4% platform

• In-house manufacturing - production takes place at Cana Laboratories, the Company's EU GMP-licensed and EMA-certified facility in Athens

• Existing quality and regulatory infrastructure - certification, testing and quality systems are shared across the wider C-Scrub range

• Brand recognition - the line extends an established brand with existing commercial relationships

Market Opportunity

The global animal health market is estimated at approximately $69 billion, with companion animal care the fastest-growing segment. According to Grand View Research, the market is projected to grow from $75.3 billion in 2026 to $156 billion by 2033, a compound annual growth rate of approximately 11%.

C-ScrubVet extends the C-Scrub franchise beyond human healthcare, where the formulation is already established across e-commerce, retail and, following EN 12791 certification in April 2026, hospital and surgical settings. Cosmos Health joins established players in the category, which include Zoetis, Boehringer Ingelheim, Elanco and Virbac, entering as a vertically integrated participant with in-house EU GMP-licensed and EMA-certified manufacturing and an established, EN-certified formulation already in commercial use.

The C-ScrubVet launch adds a new growth channel alongside Cosmos Health's core pharmaceutical and nutraceutical business, which delivered record fiscal year 2025 revenue of $65.27 million, up 20% year-over-year, and continued double-digit revenue growth in the first half of 2026. C-ScrubVet is expected to be one of several catalysts supporting the Company's previously issued 2029 guidance of $200.6 million in revenue, $44.2 million in adjusted EBITDA and $31.0 million in net income.

Distribution Strategy

Cosmos Health is pursuing a phased, multi-channel rollout for C-ScrubVet, beginning in the United Kingdom:

• United Kingdom first, Europe to follow - sales have commenced in the United Kingdom, with additional European markets targeted from Q4 2026

• E-commerce-led launch - initial sales are being conducted through e-commerce platforms, providing immediate market access and early visibility on demand ahead of a wider retail rollout

• Retail and clinical expansion - planned expansion into established pet store chains, veterinary practices and clinics is intended to convert early e-commerce traction into recurring distribution

• Established commercial infrastructure - the distribution relationships and logistics already in place across the wider C-Scrub range are expected to support a faster route to market than a standalone brand launch

Greg Siokas, CEO of Cosmos Health, stated: "Earlier this year we announced our entry into animal health. Today we are commercializing our product under the C-ScrubVet brand. This takes a formulation we already own and manufacture, and puts it in front of an entirely new customer base - pet owners, veterinary practices and equine and livestock operations - in a market worth $69 billion globally. Launching first in the United Kingdom, where C-Scrub is already established, gives us an efficient entry point, and we intend to move into additional markets and channels across Europe in Q4 2026. It is the pattern we want to repeat: extend proven, certified products into adjacent categories where we already have the manufacturing capability."

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com

SOURCE: Cosmos Health Inc.

View the original press release on ACCESS Newswire

FAQ

What is C-ScrubVet and for which animals is it intended?

C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial cleanser containing 4% chlorhexidine digluconate. It is supplied as a biocide for external use in a 500ml pump-dispenser bottle and is formulated for dogs, cats, horses, companion animals and large animals.

What certifications does C-ScrubVet hold for veterinary use?

C-ScrubVet is certified under European standards EN 1656 and EN 1657, which cover bactericidal and fungicidal activity in veterinary applications.

How is Cosmos Health rolling out C-ScrubVet geographically and across channels?

Sales have commenced in the United Kingdom via e-commerce platforms. Cosmos Health targets additional European markets from Q4 2026 and plans to expand distribution into established pet store chains as well as veterinary practices and clinics.

Where is C-ScrubVet manufactured?

C-ScrubVet is manufactured in-house at Cana Laboratories in Athens, which is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA). This facility already produces pharmaceuticals, food supplements, cosmetics, biocides and medical devices for the company.

How does C-ScrubVet relate to Cosmos Health's existing C-Scrub franchise?

C-ScrubVet builds on the existing C-Scrub Wash 4% platform used in human healthcare. The formulation is already established across e-commerce and retail and, following EN 12791 certification in April 2026, in hospital and surgical settings. The veterinary line extends this EN-certified formulation into animal health while sharing manufacturing, certification, testing and quality systems with the wider C-Scrub range.